Annual sales fell from KRW 30 billion in 2023 to KRW 27.5 billion in 2024, a decline of 8.4%, and then edged up to KRW 27.6 billion in 2025, a 0.4% rise that left them roughly flat. 2023 was the largest year in the period and 2024 the smallest.
Operating profit dropped from KRW 5.02 billion in 2023 to KRW 3.73 billion in 2024, a 25.7% decline, and recovered slightly to KRW 3.77 billion in 2025, up 1.0%.
Profit attributable to controlling shareholders was KRW 4.69 billion in 2023, KRW 3.72 billion in 2024 (down 20.7%) and KRW 4.27 billion in 2025 (up 15.0%), so the 2025 recovery did not return it to the 2023 level. Net profit including non-controlling interests was disclosed at the same levels for those years.
The operating margin fell from 16.7% in 2023 to 13.6% in 2024 and held at 13.6% in 2025, so the margin base stepped down after 2024.
Quarterly sales peaked at KRW 8.68 billion in Q4 2025, up 7.4% from the prior quarter, then moved to KRW 8.07 billion in Q1 2026, KRW 8.08 billion in Q2 and KRW 7.65 billion in Q3, which was down 5.4% year on year.
Operating profit fell from KRW 1.64 billion in Q3 2025 to KRW 739 million in Q3 2026, down 54.9% year on year, and it declined in each of the four quarters from Q4 2025 through Q3 2026.
Profit attributable to controlling shareholders also fell for three straight quarters after peaking at KRW 1.59 billion in Q4 2025, reaching KRW 724 million in Q3 2026, and the last four quarters combined total KRW 4.42 billion.
Operating profit as a share of quarterly sales dropped from roughly 20% in Q3 2025 to roughly 10% in Q3 2026, nearly halving, which points to margin pressure as the main driver of the profit decline rather than sales volume alone.
Press coverage of the first-half 2026 disclosure cited online sales, quasi-drug sales and a price increase from Q2 as profit supports, so the cause of the Q3 profit drop is a point to check in the next annual report notes and management commentary.